Arrowhead Pharmaceuticals

This early-stage trial tests a single injection of ARO-ATXN2 in 36 adults with spinocerebellar ataxia type 2, a rare genetic disorder that affects movement and coordination. The main goal is to see if the drug is safe and how the body processes it. Participants are randomly assig…

This Phase 3 study tests plozasiran, an injectable drug, in 1456 adults with high triglycerides. Participants receive 4 doses over 12 months. The goal is to see if the drug safely lowers blood fat levels compared to a placebo.

This study was designed to test ARC-520, an experimental RNAi drug, in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more effectively. However, the trial…

This study aimed to test an experimental drug called ARC-AAT in people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause liver and lung damage. The drug was designed to reduce harmful protein buildup in the liver. However, the trial was withdrawn befo…

This Phase 3 trial tests plozasiran, an injectable drug, in 446 adults with severe hypertriglyceridemia (very high blood fats). Participants receive four doses over 12 months, and researchers measure how much triglyceride levels drop compared to placebo. The goal is to see if plo…

This Phase 3 study tests a drug called plozasiran in 311 adults with severe hypertriglyceridemia, a condition where blood fat levels are very high and raise the risk of pancreatitis. Participants receive four injections over a year, either the drug or a placebo. The main goal is …